Detalhe da pesquisa
1.
Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.
Lancet Oncol
; 14(4): 371-82, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23477833
2.
PDGF receptor alpha is an alternative mediator of rapamycin-induced Akt activation: implications for combination targeted therapy of synovial sarcoma.
Cancer Res
; 72(17): 4515-25, 2012 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22787122